Last reviewed · How we verify
Placebo Folliculinum
Placebo Folliculinum is a Small molecule drug developed by Shaare Zedek Medical Center. It is currently in Phase 3 development for Psoriasis.
The exact mechanism of action of Folliculinum is not well understood.
The exact mechanism of action of Folliculinum is not well understood. Used for Psoriasis.
At a glance
| Generic name | Placebo Folliculinum |
|---|---|
| Sponsor | Shaare Zedek Medical Center |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Folliculin is a tumor suppressor protein, but its role in the treatment of diseases is still being researched.
Approved indications
- Psoriasis
Common side effects
- Local reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Folliculinum CI brief — competitive landscape report
- Placebo Folliculinum updates RSS · CI watch RSS
- Shaare Zedek Medical Center portfolio CI
Frequently asked questions about Placebo Folliculinum
What is Placebo Folliculinum?
How does Placebo Folliculinum work?
What is Placebo Folliculinum used for?
Who makes Placebo Folliculinum?
What development phase is Placebo Folliculinum in?
What are the side effects of Placebo Folliculinum?
Related
- Manufacturer: Shaare Zedek Medical Center — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Psoriasis
- Compare: Placebo Folliculinum vs similar drugs
- Pricing: Placebo Folliculinum cost, discount & access